FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085878148> ?p ?o ?g. }

• W2085878148 endingPage "1440" @default.
• W2085878148 startingPage "1432" @default.
• W2085878148 abstract "Purpose Temporal lobe (TL) parenchyma toxicity constitutes one of the most frequent late adverse event in high-dose proton therapy (PT) for tumors of the skull base. We analyzed clinical events with dosimetric parameters in our patients treated for skull base tumors with spot-scanning PT. Methods and Materials Between 1998 and 2005, a total of 62 patients received PT to a median dose of 71.7 Gy (relative biologic effectiveness [RBE]) (range, 63–74 Gy). The dose–volume histogram of each TL and the entire brain parenchyma (BP) were analyzed according to maximum, mean, and minimum dose as well as doses to 0.5, 1, 2, and 3 cc of brain volume (D0.5, D1, D2, D3) and correlated with clinical events. Generalized equivalent uniform dose (gEUD) values were calculated. Results At a mean follow-up of 38 months (range, 14–92 months), 2 patients had developed symptomatic Grade 3 and 5 patients asymptomatic Grade 1 TL toxicity. Mean doses to a 2-cc volume of BP increased from 71 ± 5 Gy (RBE) for no toxicity to 74 ± 5 Gy (RBE) for Grade 1 and to 76 ± 2 Gy (RBE) for Grade 3 toxicity. TL events occurred in 6 of 7 patients (86%) at or above dose levels of ≥64 Gy (RBE) D3, ≥68 Gy (RBE) D2, ≥72 Gy (RBE) D1, and ≥73 Gy (RBE) D0.5, respectively (p = NS). No statistically significant dose/volume threshold was detected between patients experiencing no toxicity vs. Grade 1 or Grade 3. A strong trend for Grade 1 and 3 events was observed, when the gEUD was 60 Gy. Conclusions A statistically significant normal tissue threshold dose for BP has not been successfully defined. However, our data suggest that tolerance of TL and BP to fractionated radiotherapy appears to be correlated with tissue volume included in high-dose regions. Additional follow-up time and patient accrual is likely needed to achieve clinical significance for these dose–volume parameters investigated. Our findings support the importance of establishing an organ-at-risk maximally permissible dose for BP. Temporal lobe (TL) parenchyma toxicity constitutes one of the most frequent late adverse event in high-dose proton therapy (PT) for tumors of the skull base. We analyzed clinical events with dosimetric parameters in our patients treated for skull base tumors with spot-scanning PT. Between 1998 and 2005, a total of 62 patients received PT to a median dose of 71.7 Gy (relative biologic effectiveness [RBE]) (range, 63–74 Gy). The dose–volume histogram of each TL and the entire brain parenchyma (BP) were analyzed according to maximum, mean, and minimum dose as well as doses to 0.5, 1, 2, and 3 cc of brain volume (D0.5, D1, D2, D3) and correlated with clinical events. Generalized equivalent uniform dose (gEUD) values were calculated. At a mean follow-up of 38 months (range, 14–92 months), 2 patients had developed symptomatic Grade 3 and 5 patients asymptomatic Grade 1 TL toxicity. Mean doses to a 2-cc volume of BP increased from 71 ± 5 Gy (RBE) for no toxicity to 74 ± 5 Gy (RBE) for Grade 1 and to 76 ± 2 Gy (RBE) for Grade 3 toxicity. TL events occurred in 6 of 7 patients (86%) at or above dose levels of ≥64 Gy (RBE) D3, ≥68 Gy (RBE) D2, ≥72 Gy (RBE) D1, and ≥73 Gy (RBE) D0.5, respectively (p = NS). No statistically significant dose/volume threshold was detected between patients experiencing no toxicity vs. Grade 1 or Grade 3. A strong trend for Grade 1 and 3 events was observed, when the gEUD was 60 Gy. A statistically significant normal tissue threshold dose for BP has not been successfully defined. However, our data suggest that tolerance of TL and BP to fractionated radiotherapy appears to be correlated with tissue volume included in high-dose regions. Additional follow-up time and patient accrual is likely needed to achieve clinical significance for these dose–volume parameters investigated. Our findings support the importance of establishing an organ-at-risk maximally permissible dose for BP." @default.
• W2085878148 created "2016-06-24" @default.
• W2085878148 creator A5035870007 @default.
• W2085878148 creator A5039635187 @default.
• W2085878148 creator A5044733192 @default.
• W2085878148 creator A5047461923 @default.
• W2085878148 creator A5057583620 @default.
• W2085878148 creator A5064668846 @default.
• W2085878148 creator A5081979421 @default.
• W2085878148 creator A5083635288 @default.
• W2085878148 date "2012-08-01" @default.
• W2085878148 modified "2023-10-15" @default.
• W2085878148 title "Temporal Lobe Toxicity Analysis After Proton Radiation Therapy for Skull Base Tumors" @default.
• W2085878148 cites W1976996553 @default.
• W2085878148 cites W1979366136 @default.
• W2085878148 cites W1982768545 @default.
• W2085878148 cites W2005456723 @default.
• W2085878148 cites W2028971946 @default.
• W2085878148 cites W2040145532 @default.
• W2085878148 cites W2055834915 @default.
• W2085878148 cites W2066616656 @default.
• W2085878148 cites W2071418795 @default.
• W2085878148 cites W2086479790 @default.
• W2085878148 cites W2088948537 @default.
• W2085878148 cites W2092201288 @default.
• W2085878148 cites W2135622764 @default.
• W2085878148 cites W2137898685 @default.
• W2085878148 cites W2150090970 @default.
• W2085878148 cites W2154597590 @default.
• W2085878148 cites W2170560268 @default.
• W2085878148 doi "https://doi.org/10.1016/j.ijrobp.2011.10.042" @default.
• W2085878148 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22349042" @default.
• W2085878148 hasPublicationYear "2012" @default.
• W2085878148 type Work @default.
• W2085878148 sameAs 2085878148 @default.
• W2085878148 citedByCount "51" @default.
• W2085878148 countsByYear W20858781482013 @default.
• W2085878148 countsByYear W20858781482014 @default.
• W2085878148 countsByYear W20858781482015 @default.
• W2085878148 countsByYear W20858781482016 @default.
• W2085878148 countsByYear W20858781482017 @default.
• W2085878148 countsByYear W20858781482018 @default.
• W2085878148 countsByYear W20858781482019 @default.
• W2085878148 countsByYear W20858781482020 @default.
• W2085878148 countsByYear W20858781482021 @default.
• W2085878148 countsByYear W20858781482022 @default.
• W2085878148 countsByYear W20858781482023 @default.
• W2085878148 crossrefType "journal-article" @default.
• W2085878148 hasAuthorship W2085878148A5035870007 @default.
• W2085878148 hasAuthorship W2085878148A5039635187 @default.
• W2085878148 hasAuthorship W2085878148A5044733192 @default.
• W2085878148 hasAuthorship W2085878148A5047461923 @default.
• W2085878148 hasAuthorship W2085878148A5057583620 @default.
• W2085878148 hasAuthorship W2085878148A5064668846 @default.
• W2085878148 hasAuthorship W2085878148A5081979421 @default.
• W2085878148 hasAuthorship W2085878148A5083635288 @default.
• W2085878148 hasConcept C111337013 @default.
• W2085878148 hasConcept C11928243 @default.
• W2085878148 hasConcept C121332964 @default.
• W2085878148 hasConcept C126322002 @default.
• W2085878148 hasConcept C126838900 @default.
• W2085878148 hasConcept C185544564 @default.
• W2085878148 hasConcept C197934379 @default.
• W2085878148 hasConcept C2777910003 @default.
• W2085878148 hasConcept C2779244869 @default.
• W2085878148 hasConcept C29730261 @default.
• W2085878148 hasConcept C2989005 @default.
• W2085878148 hasConcept C509974204 @default.
• W2085878148 hasConcept C71924100 @default.
• W2085878148 hasConceptScore W2085878148C111337013 @default.
• W2085878148 hasConceptScore W2085878148C11928243 @default.
• W2085878148 hasConceptScore W2085878148C121332964 @default.
• W2085878148 hasConceptScore W2085878148C126322002 @default.
• W2085878148 hasConceptScore W2085878148C126838900 @default.
• W2085878148 hasConceptScore W2085878148C185544564 @default.
• W2085878148 hasConceptScore W2085878148C197934379 @default.
• W2085878148 hasConceptScore W2085878148C2777910003 @default.
• W2085878148 hasConceptScore W2085878148C2779244869 @default.
• W2085878148 hasConceptScore W2085878148C29730261 @default.
• W2085878148 hasConceptScore W2085878148C2989005 @default.
• W2085878148 hasConceptScore W2085878148C509974204 @default.
• W2085878148 hasConceptScore W2085878148C71924100 @default.
• W2085878148 hasIssue "5" @default.
• W2085878148 hasLocation W20858781481 @default.
• W2085878148 hasLocation W20858781482 @default.
• W2085878148 hasOpenAccess W2085878148 @default.
• W2085878148 hasPrimaryLocation W20858781481 @default.
• W2085878148 hasRelatedWork W2335821915 @default.
• W2085878148 hasRelatedWork W2461860432 @default.
• W2085878148 hasRelatedWork W2469685510 @default.
• W2085878148 hasRelatedWork W2802766591 @default.
• W2085878148 hasRelatedWork W2898672813 @default.
• W2085878148 hasRelatedWork W2944246952 @default.
• W2085878148 hasRelatedWork W2963212139 @default.
• W2085878148 hasRelatedWork W2973129228 @default.
• W2085878148 hasRelatedWork W3036401222 @default.
• W2085878148 hasRelatedWork W4220655749 @default.
• W2085878148 hasVolume "83" @default.

• next